上皮性卵巢癌中的错配修复缺陷、微卫星不稳定性与Lynch综合征:系统综述与Meta分析
该系统综述与Meta分析纳入55项研究,评估上皮性卵巢癌中错配修复缺陷(MMRd)、微卫星不稳定性高(MSI-high)及Lynch综合征(LS)的患病率与LS筛查试验的诊断准确性。结果显示EOC中MMRd、MSI-high、LS患病率分别为6%、13%、2%;MMRd与MSI-high在子宫内膜样亚型最高,浆液性最低;同步性卵巢子宫内膜癌MMRd与MSI-high率均达28%。作者认为非浆液非黏液性EOC尤其子宫内膜样应考虑MMRd与胚系LS检测。
要点
- 上皮性卵巢癌中MMRd、MSI-high、LS患病率分别为6%、13%、2%。
- 子宫内膜样亚型MMRd与MSI-high患病率最高,浆液性亚型最低。
- 同步性卵巢子宫内膜癌MMRd与MSI-high率均达28%,LS致病性变异为7%。
核心结论
- 作者认为非浆液非黏液性上皮性卵巢癌尤其子宫内膜样亚型应考虑MMRd与胚系LS检测。
研究设计与样本
- 系统综述与Meta分析,系统检索MEDLINE、Epub Ahead of Print、MEDLINE In-Process and Other Non-Indexed Citations、Cochrane Central Register of Controlled Trials及Embase数据库。
- 纳入通过测序分析MMR、MSI和/或LS的研究,共纳入55项研究。
主要发现
- 上皮性卵巢癌中MMRd患病率为6%(95%CI 5-8%),MSI-high为13%(95%CI 12-15%),LS为2%(95%CI 1-3%)。
- MLH1缺陷患者中76%存在超甲基化(95%CI 64-84%)。
- MMRd患病率在子宫内膜样亚型最高为12%,非浆液非黏液性为9%,浆液性最低为1%。
- MSI-high患病率在子宫内膜样与非浆液非黏液性均为12%,浆液性最低为9%。
- 同步性及子宫内膜样EOC的LS致病性变异患病率分别为7%和3%,浆液性最低为1%;同步性卵巢子宫内膜癌MMRd与MSI-high率均达28%。
关键数值与推荐
- LS筛查试验敏感性最高为免疫组化(IHC)91.1%与IHC联合MSI 92.8%,特异性最高为IHC联合甲基化检测92.3%。
临床怎么用
- 作者认为非浆液非黏液性EOC尤其子宫内膜样应考虑MMRd与胚系LS检测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Investigating for mismatch repair protein deficiency (MMRd), microsatellite instability (MSI), and Lynch syndrome (LS) is widely accepted in endometrial cancer, but knowledge is limited on its value in epithelial ovarian cancer (EOC). The primary objective was to evaluate the prevalence of mismatch repair protein deficiency (MMRd), microsatellite instability (MSI)-high, and Lynch syndrome (LS) in epithelial ovarian cancer (EOC), as well as the diagnostic accuracy of LS screening tests. The secondary objective was to determine the prevalence of MMRd, MSI-high, and LS in synchronous ovarian endometrial cancer and in histological subtypes. METHODS: We systematically searched the MEDLINE, Epub Ahead of Print, MEDLINE In-Process and Other Non-Indexed Citations, Cochrane Central Register of Controlled Trials, and Embase databases. We included studies analysing MMR, MSI, and/or LS by sequencing. RESULTS: A total of 55 studies were included. The prevalence of MMRd, MSI-high, and LS in EOC was 6% (95% confidence interval (CI) 5-8%), 13% (95% CI 12-15%), and 2% (95% CI 1-3%) respectively. Hypermethylation was present in 76% of patients with MLH1 deficiency (95% CI 64-84%). The MMRd prevalence was highest in endometrioid (12%) followed by non-serous non-mucinous (9%) and lowest in serous (1%) histological subtypes. MSI-high prevalence was highest in endometrioid (12%) and non-serous non-mucinous (12%) and lowest in serous (9%) histological subtypes. Synchronous and endometrioid EOC had the highest prevalence of LS pathogenic variants at 7% and 3% respectively, with serous having lowest prevalence (1%). Synchronous ovarian and endometrial cancers had highest rates of MMRd (28%) and MSI-high (28%). Sensitivity was highest for IHC (91.1%) and IHC with MSI (92.8%), while specificity was highest for IHC with methylation (92.3%). CONCLUSION: MMRd and germline LS testing should be considered for non-serous non-mucinous EOC, particularly for endometrioid. PRECIS: The rates of mismatch repair deficiency, microsatellite instability high, and mismatch repair germline mutations are highest in endometrioid subtype and non-serous non-mucinous ovarian cancer. The rates are lowest in serous histologic subtype.
引用
- Mitric C, Salman L, Abrahamyan L, et al. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 2023. PMID: 36682091. doi:10.1016/j.ygyno.2022.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。